Effects of the sibutramine therapy on pulmonary artery pressure in obese patients


Guven A., Koksal N., Cetinkaya A., Sokmen G., Ozdemir R.

DIABETES OBESITY & METABOLISM, cilt.6, ss.50-55, 2004 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 6 Konu: 1
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1111/j.1463-1326.2004.00314.x
  • Dergi Adı: DIABETES OBESITY & METABOLISM
  • Sayfa Sayıları: ss.50-55

Özet

Aim: Obesity is a major global public health problem. Previous drugs (dexfenfluramine and fenfluramine) used for the treatment of obesity have been withdrawn due to various cardiac side effects. Sibutramine is an anti-obesity agent. The purpose of this study was to assess cardiac valve disease and pulmonary artery pressure (PAP) of the patients who used once daily doses of sibutramine.